222 related articles for article (PubMed ID: 11156524)
1. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.
Yu D; Hung MC
Oncogene; 2000 Dec; 19(53):6115-21. PubMed ID: 11156524
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Chen FL; Xia W; Spector NL
Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
Tan M; Lan KH; Yao J; Lu CH; Sun M; Neal CL; Lu J; Yu D
Cancer Res; 2006 Apr; 66(7):3764-72. PubMed ID: 16585203
[TBL] [Abstract][Full Text] [Related]
4. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
[TBL] [Abstract][Full Text] [Related]
5. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
[TBL] [Abstract][Full Text] [Related]
6. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
[TBL] [Abstract][Full Text] [Related]
7. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer.
Kauraniemi P; Kallioniemi A
Endocr Relat Cancer; 2006 Mar; 13(1):39-49. PubMed ID: 16601278
[TBL] [Abstract][Full Text] [Related]
8. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
Xia W; Gerard CM; Liu L; Baudson NM; Ory TL; Spector NL
Oncogene; 2005 Sep; 24(41):6213-21. PubMed ID: 16091755
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro.
Ma C; Lin H; Leonard SS; Shi X; Ye J; Luo J
Oncogene; 2003 Aug; 22(34):5281-90. PubMed ID: 12917629
[TBL] [Abstract][Full Text] [Related]
10. Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells.
Singer CF; Hudelist G; Fuchs EM; Köstler W; Fink-Retter A; Gschwantler-Kaulich D; Gnant M; Lamm W; Rudas M; Czerwenka K; Kubista E
Endocr Relat Cancer; 2009 Mar; 16(1):73-83. PubMed ID: 18948375
[TBL] [Abstract][Full Text] [Related]
11. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.
Zhao YH; Zhou M; Liu H; Ding Y; Khong HT; Yu D; Fodstad O; Tan M
Oncogene; 2009 Oct; 28(42):3689-701. PubMed ID: 19668225
[TBL] [Abstract][Full Text] [Related]
13. Role of erbB2 in breast cancer chemosensitivity.
Yu D; Hung MC
Bioessays; 2000 Jul; 22(7):673-80. PubMed ID: 10878580
[TBL] [Abstract][Full Text] [Related]
14. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
Kunz C; Borghouts C; Buerger C; Groner B
Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
[TBL] [Abstract][Full Text] [Related]
15. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions.
Spangenberg C; Lausch EU; Trost TM; Prawitt D; May A; Keppler R; Fees SA; Reutzel D; Bell C; Schmitt S; Schiffer IB; Weber A; Brenner W; Hermes M; Sahin U; Türeci O; Koelbl H; Hengstler JG; Zabel BU
Cancer Res; 2006 Apr; 66(7):3715-25. PubMed ID: 16585198
[TBL] [Abstract][Full Text] [Related]
16. A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth.
Kawa S; Matsushita H; Ohbayashi H; Semba K; Yamamoto T
Biochem Biophys Res Commun; 2009 Jul; 384(3):329-33. PubMed ID: 19409371
[TBL] [Abstract][Full Text] [Related]
17. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
18. Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy.
Hirsch DS; Wu WJ
Expert Rev Anticancer Ther; 2007 Feb; 7(2):147-57. PubMed ID: 17288526
[TBL] [Abstract][Full Text] [Related]
19. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
Zhan L; Xiang B; Muthuswamy SK
Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
[TBL] [Abstract][Full Text] [Related]
20. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D
Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]